A patient had surgery for tenolysis of the finger flexor tendons. At the conclusion of the case, reconstituted connective tissue was injected along the flexor tendon sheaths. The injection was intended to augment damaged tissues with functional tissue, provide structural support at the surgical site, and aid in the body's constructive remodeling process. Should this procedure be reported with unlisted procedure code 20999 , which is comparable to injection code 20550 , or reported with unlisted procedure code 26989 , which is comparable to tissue augmentation code 15777 ? ...

Subscribe or sign in to view the full article.

Sign In Subscribe Today

Note:  The following article synopsis was NOT provided by the AMA. It was created by Find-A-Code/innoviHealth.

Article Overview

This article discusses a coding scenario involving finger flexor tendon tenolysis followed by injection of a reconstituted connective tissue product along the tendon sheaths. It explains the general reporting issue, the role of unlisted procedure codes and comparable procedure concepts, and the possibility of separate facility reporting for the product using HCPCS. It is relevant to professional and facility coders, billers, and reimbursement staff working with surgical procedures and orthopaedic/hand cases.

Why This Topic Matters

End-of-case product injections can create uncertainty about whether they are separately reportable and which code families or modifiers are relevant. Correct interpretation affects professional coding, facility billing, and documentation requirements.

Modifiers Discussed

• CPT: 22

Subscribe or sign in to view the full article.

Sign In Subscribe Today